Outlook Therapeutics (OTLK) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Outlook Therapeutics (OTLK) is Moderate Underperform.

The composite score behind that read is -0.30, weighing +0.00 of bullish evidence against -0.43 bearish.

Outlook Therapeutics last closed at $0.60, +7.14% on the session.

Against the IVW growth benchmark the position is +6.34% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

20 graded predictions for OTLK so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Outlook Therapeutics in the 98th percentile on return on equity, where 100 is best.

Outlook Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $137.30M.

StockMap tracks Outlook Therapeutics as the 269th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Outlook Therapeutics ranks 368th of 381 in the group, against a group median of -0.08.